Clinical Trial Update: Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG) [Phase 2]

View source ↗

Summary

Phase 2 trial in chronic lymphocytic leukemia evaluating a sequential regimen of bendamustine debulking followed by CAL-101 (idelalisib) and GA101 (obinutuzumab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• CAL-101 (idelalisib) (idelalisib)
• GA101 (obinutuzumab) (obinutuzumab)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphocytic Leucemia | Phase 2 | Status: COMPLETED